Gujarat Themis Biosyn Ltd.
NSE: GUJTHEM · Pharmaceuticals
Snapshot
Unlock Gujarat Themis Biosyn Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gujarat Themis Biosyn Limited is an Indian pharmaceutical company specialising in the manufacture of bulk drugs and medicinal chemicals. Its product portfolio includes key intermediates such as Rifamycin-S, Rifamycin-O, and Lovastatin, which are utilised in treating various infectious and chronic conditions.
Business Model
The company operates primarily as a manufacturer of bulk drugs, often engaging in job work arrangements to serve the pharmaceutical industry. It leverages its manufacturing capabilities to produce specialised chemical intermediates for domestic and potentially international markets.
- Incorporation Year:1981
Growth Outlook
Growth is driven by the sustained demand for tuberculosis and infectious disease treatments, where the company's Rifamycin-based products play a critical role. Future prospects depend on the company's ability to maintain manufacturing efficiency and secure new job work contracts.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards that, if breached, could lead to operational disruptions.
- Concentration Risk. Reliance on a limited portfolio of bulk drugs and intermediates makes the company vulnerable to fluctuations in demand for specific therapeutic areas.
- Input Cost Volatility. Fluctuations in the prices of raw materials and chemical precursors can significantly impact the company's manufacturing margins.
- Competitive Pressure. The bulk drug manufacturing sector in India is highly competitive, potentially pressuring pricing and contract terms for job work services.
Start your research today
Unlock AI insights, financials, peers and live data on Gujarat Themis Biosyn Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹174 Cr
TTM · standalone
NET PROFIT
₹49 Cr
TTM · standalone
EPS
₹2.64
TTM · standalone
RETURN ON EQUITY
18.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
19.8%
TTM · standalone
P/E
144.6×
Q1 FY27 · standalone
EV/EBITDA
54.7x
Q1 FY27 · standalone
EBITDA MARGIN
48.8%
TTM · standalone
DEBT TO EQUITY
0.6x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,476 Cr | 144.6× | 54.69 | 17.5% | 48.8% | 18.2% | 19.8% | -4.9% |
Zota Health Care LimitedZOTA | ₹4,816 Cr | -40.4× | 416.98 | 78.9% | 1.9% | -22.7% | -14.6% | -11.9% |
SMS Pharmaceuticals LimitedSMSPHARMA | ₹4,523 Cr | 41.9× | 26.55 | 10.2% | 20.3% | 14.4% | 15.5% | +82.7% |
Gufic Biosciences LimitedGUFICBIO | ₹4,387 Cr | 57.2× | 28.23 | 16.7% | 17.0% | 11.6% | 16.9% | +19.2% |
Unichem Laboratories LimitedUNICHEMLAB | ₹4,036 Cr | 12.2× | 14.03 | 9.4% | 13.0% | 11.8% | 14.1% | +10.9% |
Aarti Drugs LimitedAARTIDRUGS | ₹3,982 Cr | 20.1× | 13.53 | — | 12.6% | 13.1% | 14.5% | -13.7% |
As of Q1 FY27
Financials
Gujarat Themis Biosyn Ltd.
NSE: GUJTHEM · Pharmaceuticals
Snapshot
Unlock Gujarat Themis Biosyn Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gujarat Themis Biosyn Limited is an Indian pharmaceutical company specialising in the manufacture of bulk drugs and medicinal chemicals. Its product portfolio includes key intermediates such as Rifamycin-S, Rifamycin-O, and Lovastatin, which are utilised in treating various infectious and chronic conditions.
Business Model
The company operates primarily as a manufacturer of bulk drugs, often engaging in job work arrangements to serve the pharmaceutical industry. It leverages its manufacturing capabilities to produce specialised chemical intermediates for domestic and potentially international markets.
- Incorporation Year:1981
Growth Outlook
Growth is driven by the sustained demand for tuberculosis and infectious disease treatments, where the company's Rifamycin-based products play a critical role. Future prospects depend on the company's ability to maintain manufacturing efficiency and secure new job work contracts.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards that, if breached, could lead to operational disruptions.
- Concentration Risk. Reliance on a limited portfolio of bulk drugs and intermediates makes the company vulnerable to fluctuations in demand for specific therapeutic areas.
- Input Cost Volatility. Fluctuations in the prices of raw materials and chemical precursors can significantly impact the company's manufacturing margins.
- Competitive Pressure. The bulk drug manufacturing sector in India is highly competitive, potentially pressuring pricing and contract terms for job work services.
Start your research today
Unlock AI insights, financials, peers and live data on Gujarat Themis Biosyn Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹174 Cr
TTM · standalone
NET PROFIT
₹49 Cr
TTM · standalone
EPS
₹2.64
TTM · standalone
RETURN ON EQUITY
18.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
19.8%
TTM · standalone
P/E
144.6x
Q1 FY27 · standalone
EV/EBITDA
54.7x
Q1 FY27 · standalone
EBITDA MARGIN
48.8%
TTM · standalone
DEBT TO EQUITY
0.6x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27